Neoadjuvant Combination Immunotherapy for Stage III Melanoma

Determine safety and efficacy of pre-operative combination immunotherapy with Talimogene Laherparepvec (T-VEC)/Pembrolizumab given prior to complete lymph node dissection in resectable stage 3 cutaneous melanoma with clinically apparent lymph node metastases.

Trial Details

NCT ID
NCT03842943
Phase
PHASE2
Sponsor
University of Louisville
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • Pembrolizumab
  • Talimogene Laherparepvec
Locations (sample)
  • Louisville, Kentucky, United States|38.25424,-85.75941

Key Eligibility Criteria

  • 18 years of age, any race or sex, who have pathologically confirmed cutaneous melanoma
  • ECOG performance status of 0 or 1
  • Adequate hematologic, hepatic, renal and coagulation function
  • Must have measurable disease and have an injectable target lymph node for intralesional therapy administration

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →